leadf
logo-loader
viewEXMceuticals

EXMceuticals secures critical R&D license for its Portugal cannabis facilities

EXMceuticals Inc's (CSE:EXM) Jonathan Summers speaks to Proactive London's Andrew Scott following the news they've obtained a licence for cannabis research and development from the Portuguese government.

The license was granted by INFARMED - the Portuguese National Authority of Medicines and Health Products. 

Summers says it allows them to now take a huge step forward in its European operations by being able to import, research and refine cannabinoids and cannabis by-products.

Quick facts: EXMceuticals

Price: 0.16 CAD

CSE:EXM
Market: CSE
Market Cap: $6.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of EXMceuticals named herein, including the promotion by the Company of EXMceuticals in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

EXMceuticals now '100% focused on being a refining bioscience business in...

EXMceuticals Inc's (CSE:EXM) Jonathan Summers speaks to Proactive London's Katie Pilbeam about their cannabis research and development. Summers explains that the company has recently transitioned from being active in Africa to focusing their attentions solely onto Portugal. The company...

on 14/9/20

2 min read